Retrospective Analysis of Clinical Outcomes of Utilizing R-CHOP Plus Zanubrutinib for High-Risk Diffuse Large B Cell Lymphoma Patients with Extranodal Involvement or MYC/BCL2 Double Expression
- Resource Type
- Article
- Authors
- Fu, Wanbin; Liu, Jia; Xiao, Dan; Zhao, Huanbin; Wang, Ting; Hu, Jiong; Hou, Jian; Zhong, Hua; Xu, Lan
- Source
- Blood; November 2023, Vol. 142 Issue: 1, Number 1 Supplement 1 p6323-6323, 1p
- Subject
- Language
- ISSN
- 00064971; 15280020
Background:Diffuse large B-cell lymphoma (DLBCL) patients with extranodal involvement and double expression of MYC and BCL2 often have a poorer prognosis when treated with the standard first-line R-CHOP regimen. The 5-year progression-free survival (PFS) and overall survival (OS) rates are both below 40% for these high-risk DLBCL cases. In this study, we perform a retrospective analysis of the clinical outcomes and adverse events of the high-risk DLBCL patients with extranodal involvement and double expression, who were admitted to our center and used Bruton's tyrosine kinase inhibitor (BTKi) zanubrutinib on the basis of R-CHOP regimen.